Thorough QT/QTc Study in Patients With Advanced Parkinson's Disease: Cardiac Safety of Rotigotine
Authors:
- 23 July 2008
- journal article
- research article
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 84 (5) , 595-603
Abstract
The potential effects of the dopamine agonist rotigotine on cardiac repolarization were studied in patients with Parkinson's disease, which affects electrocardiogram (ECG) quality. The parallel-group trial was double-blind and placebo- and positive (moxifloxacin 400 mg)-controlled. After two 24-h baseline ECGs, patients were randomized to rotigotine (n = 66) or placebo (n = 64). Twenty four-hour ECGs were recorded on days 14/15, 21/22, 28/29, 35/36, and 42/43 of a regimen involving weekly dose escalations of 4 mg/24 h (4 mg/24 h-24 mg/24 h). In 10-s ECGs (n = 357,948) selected from 24-h records, QT measurements were manually verified and individually rate-corrected (QTc). Assay sensitivity showed maximum mean 13.5 ms QTc prolongation after moxifloxacin with 95% confidence interval (CI) 11.8-15.2 ms. Rotigotine vs. placebo differences in time-matched changes from baseline (54 data points/24 h) showed mean effects close to zero with upper one-sided 95% CI <5 ms. Accurate, thorough QTc studies are possible even in patients with diseases that profoundly affect ECG quality. Rotigotine in supra- and therapeutic doses was shown not to affect cardiac repolarization.Keywords
This publication has 21 references indexed in Scilit:
- Rotigotine transdermal patch in early Parkinson's disease: A randomized, double‐blind, controlled study versus placebo and ropiniroleMovement Disorders, 2007
- Levocetirizine does not prolong the QT/QTc interval in healthy subjects: results from a thorough QT studyEuropean Journal of Clinical Pharmacology, 2007
- Rotigotine transdermal patch in the treatment of Parkinson’s disease and restless legs syndromeExpert Opinion on Pharmacotherapy, 2007
- Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind, double-dummy, randomised controlled trialThe Lancet Neurology, 2007
- Advanced Parkinson disease treated with rotigotine transdermal systemNeurology, 2007
- Circulating microemboli in patients with myeloproliferative disordersEuropean Journal of Neurology, 2007
- Man Versus Machine: Is There an Optimal Method for QT Measurements in Thorough QT Studies?The Journal of Clinical Pharmacology, 2006
- Parkinson’s tremor mimicking ventricular tachycardiaAge and Ageing, 2005
- Autonomic dysfunction in Parkinson's diseaseNeurologic Clinics, 2004
- Oral anticoagulation for ECG tremor artefact simulating atrial fibrillationActa Cardiologica, 2003